EMERGERS
Equity Research of
Nordic Growth Companies
EMERGERS
Equity Research of
Nordic Growth Companies
Long overdue, Nanexa has finally signed a global, exclusive license and collaboration agreement...
Following the strong semaglutide data reported earlier this year, Nanexa’s Q2 update points to...
Crunchfish’s Q2 report largely reinforces the investment case outlined in our previous update,...
Crunchfish’s Q1 report reinforces the strategic and commercial positioning already highlighted in...
Johan Widmark | 2026-05-13 08:00 Read the report in PDF here Executive Summary Following its...
Following the license agreement with Moderna in Q4’25, Nanexa continues to advance along three...
Not quite in the form we had expected, but with the Chairman and CEO committing to subscribe for...
Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in...
